FindMyKOL
Clinical trialNCT02650804CompletedPhase 2Interventional

BPM31510 Administered Intravenously With Gemcitabine in Advanced Pancreatic Cancer Patients

SponsorBPGbioEnrollment45Pancreatic Cancer
View the registry record on ClinicalTrials.gov

Summary

The lay summary the sponsor registered on ClinicalTrials.gov.

This is a Phase 2 multicenter, open-label, non-randomized study to examine the safety and effectiveness of BPM31510 administered over 144-hours (two 72-hour 110mg/Kg doses) continuous intravenous (IV) infusion in combination with gemcitabine in advanced pancreatic cancer patients as 2nd / 3rd line therapy. The study will enroll up to 25 patients in the US and Europe.
clinicaltrials.gov ↗

Investigators

The overall officials registered on this study. Names that resolve to a FindMyKOL profile link to it; the rest are shown as registered.

A profile link is shown only when the registered name resolves to a person record with a confident, namesake-checked match; ambiguous names stay unlinked.

Sites

12 registered facilities, with the per-site recruitment status where the registry publishes one. ClinicalTrials.gov does not publish per-site enrollment counts.

United Kingdom
  • the Beatson West of Scotland Cancer Centre

    Glasgow, Strathclyde, United Kingdom

  • Royal Free London Nhs Foundation Trust

    London, United Kingdom

  • St Bartholomew'S Hospital

    London, United Kingdom

United States
  • Banner Health

    Gilbert, Arizona, United States

  • Mayo Clinic

    Phoenix, Arizona, United States

  • Global Cancer Research Institute, Inc.

    Gilroy, California, United States

  • Sarcoma Oncology Research Center

    Santa Monica, California, United States

  • Beth Israel Deaconess Medical Center

    Boston, Massachusetts, United States

  • Atlantic Health System Morristown Medical Center

    Morristown, New Jersey, United States

  • Vita Medical Associates, P.C.

    Bethlehem, Pennsylvania, United States

  • Mary Crowley Cancer Research Center

    Dallas, Texas, United States

  • Medical College of Wisconsin

    Milwaukee, Wisconsin, United States

Site investigator names are published by ClinicalTrials.gov only while a study recruits, so completed studies list sites without them.

Drugs studied

The drug and biological interventions registered on this study, normalized to their RxNorm ingredient where possible.

BPM31510 Nanosuspension InjectionGemcitabine →
Linked drugs open the directory filtered to KOLs working with them.clinicaltrials.gov ↗

Registration & key dates

Registry attributes as recorded on the ClinicalTrials.gov study record.

Start
6 Jul 2016
Primary completion
11 Jun 2019
Completion
11 Jun 2019
Last update posted
26 Mar 2025
Registered enrollment
45
Registry id
NCT02650804
clinicaltrials.gov ↗

Source: ClinicalTrials.gov, via the CTTI AACT database, data as of 24 Aug 2026. Registry facts are shown as registered by the study sponsor; FindMyKOL does not interpret them.